Amgen Inc. (AMGN)
$
311.55
+4.60 (1.48%)
Key metrics
Financial statements
Free cash flow per share
19.2297
Market cap
168.5 Billion
Price to sales ratio
5.0421
Debt to equity
10.2261
Current ratio
1.2568
Income quality
3.3179
Average inventory
7.2 Billion
ROE
0.6718
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics focusing on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. The company reported an income before tax of $4,609,000,000.00 showcasing its pre-tax profitability. The EBITDA is $13,356,000,000.00 a key indicator of the company's operational profitability, while the operating income ratio is 0.22 indicating the company's operational profitability margin. Additionally, the gross profit ratio is 0.62 reflecting the efficiency of the company's production and sales operations. The company's stock is identified with the symbol 'AMGN' in the market, representing a significant asset for investors. Amgen's product portfolio includes treatments such as Enbrel for plaque psoriasis and rheumatoid arthritis, Neulasta for patients with low white blood cell counts due to cancer, Prolia for osteoporosis in postmenopausal women, and Repatha to reduce cardiovascular risks, among others. It also engages in several collaboration agreements to develop innovative therapies, such as its partnership with Novartis Pharma AG and Kyowa Kirin Co., Ltd. Trading at a price of $313.22 the stock is positioned in the higher-end market, reflecting the company's strong market presence. Furthermore, the stock has a high average trading volume of 3,138,795.00 indicating strong liquidity and investor interest. With a large market capitalization of $167,366,217,750.00 the company is a dominant player in the biotechnology industry, contributing significantly to the overall market landscape. Amgen Inc. operates within the Healthcare sector, driving innovation and growth through its cutting-edge research and product development. Its offerings, including Otezla, Aranesp, and KYPROLIS, illustrate its commitment to providing impactful therapies for various health conditions. By serving healthcare providers across multiple channels, including hospitals and pharmacies, Amgen focuses on delivering solutions that enhance patient outcomes. The company's collaborations with firms like Neumora Therapeutics and Plexium underscore its strategic approach to expanding its therapeutic portfolio, positioning it to remain a key player in a constantly evolving industry.
What is Amgen Inc. (AMGN)'s stock forecast?
Analysts predict Amgen Inc. stock to fluctuate between $253.30 (low) and $346.85 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Amgen Inc.'s market capitalization?
As of 2025-04-01, Amgen Inc.'s market cap is $167,366,217,750, based on 537,205,000 outstanding shares.
How does Amgen Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Amgen Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Amgen Inc. (AMGN) stock?
To buy Amgen Inc. (AMGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AMGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Amgen Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Amgen Inc. perform in the last earnings report?
Revenue: $33,424,000,000 | EPS: $7.56 | Growth: -39.81%.
Where can I find Amgen Inc.'s investor relations reports?
Visit https://www.amgen.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Amgen Inc.?
You can explore historical data from here
What is the all-time high and low for Amgen Inc. stock?
All-time high: $346.85 (2024-07-25) | All-time low: $198.64 (2021-12-01).
What are the key trends affecting Amgen Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.
youtube.com
Kevin Simpson, Capital Wealth Planning founder and CIO, joins CNBC's "Halftime Report" to detail his latest portfolio buys.
proactiveinvestors.com
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
youtube.com
Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.
zacks.com
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
zacks.com
The latest trading day saw Amgen (AMGN) settling at $317.17, representing a +1.1% change from its previous close.
zacks.com
New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with generalized myasthenia gravis.
seekingalpha.com
Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual mechanism and less frequent dosing could enhance weight loss and diabetes management, potentially capturing a significant market share. Analysts project MariTide could generate $5 billion in peak annual revenue, bolstering Amgen's growth amidst competition from Eli Lilly, Novo Nordisk, and others.
See all news
